**Specifications Table**TableSubject areaMedical PhysicsMore specific subject areaDescribe the bone mineral density (BMD) of patients with beta thalassemiaType of dataTablesHow data was acquiredTo calculate the bone mineral density, All medical records of patients older than 15 years were reviewed. Patients demography were extracted, the results of the BMD and *Z*-Score of femoral neck and lumbar vertebrae were reported comparing normal matched subjects. *Z*-Scores \<−1, −1 to −2.5, and bigger than −2.5 were considered as Normal, osteopenia and osteoporotic respectively.Data formatRaw, AnalyzedExperimental factorsThe mentioned parameters above, in abstract section, were analyzed according to the standards for *Z*-Score.Experimental featuresThe *Z*-Scores were determined.Data source locationAhvaz province, Iran.Data accessibilityThe data are available whit this article

**Value of the data**•This study showed bone mineral density reduced with increasing age (*p*\<0.03).•Measured BMD had a better status in the femoral region than in the lumbar region.•Since the patients were in puberty, there was a significant correlation between the use of sex hormones and BMD.•The bone mineral density increased in patients who taking bisphosphonates.

1. Data {#s0005}
=======

The participants included 81 male and 103 female patients with transfusion-dependent thalassemia (β-thalassemia). As seen in [Table 1](#t0005){ref-type="table"}, the mean age of the participants was 23.4±8.0 years (range: 15--31 years). Based on the *Z*-scores at the lumbar spine, 198 patients (82%) had low BMD (*Z* ≤−2) and 40 (18%) had normal BMD (*Z* ≥−1). Meanwhile, low BMD in the neck of the femur was only seen in 18% of the participants. A significant correlation between age and bone mineral density were found (*P*\<0.03). Per year to 2.8 percent of bone mineral density scores are low. The severity of the disease was higher in men than in women (*P*\<00.02). A negative significant correlation was detected between BMD and the mean of hematocrit in the last 5 years (*P*\<0.005). There was significant differences between Sex hormone and bone density (*P*\<0.02). The significant relationship between Hydroxyl urea consumption and bone mineral density was seen (*P*\<00.01). A significant relationship between the use of bisphosphonates and bone density exists so that the bone mineral density in patients taking bisphosphonates have been increased (*P*\<0.02). The patients who used calcium+vitamin D had no significant difference with the others in terms of BMD. Moreover, no significant correlation was found between the use of calcitriol and BMD.Table 1Demographic features of patients (confidence interval=95%).Table 1**Demographic features of patientsTime consuming(year)**Calcium+Vitamin D of consuming time to first measurement1/8±2/4Calcium+Vitamin D of consuming time to the second measurement time6/3±3Calcium+Vitamin D starting age22±7Age of onset of sex hormones15±6Duration of sex hormones to first measure6/3±4Duration of sex hormones to the second measure9/6±3Age of onset of Calcitriol21±7Calcitriol duration of the first measure2±3Calcitriol use to measure a second time6±3Age starting bisphosphonate22±7bisphosphonate use to measure of the first time1±2bisphosphonate use to measure a second time2/3±2Age starting hydroxyurea16/5±6hydroxyurea use to measure of the first time5/9±3/6hydroxyurea use to measure a second time6/2±3/2

2. Experimental design, materials and methods {#s0010}
=============================================

A total of 216 patients (age\>15 years) with transfusion-dependent thalassemia who visited Shafa Hospital (Ahwaz, Iran) participated in this prospective study. Their BMD had been annually monitored from age 10. The bone density in 216 patients (81 males and 103 females) who are suffering from thalassemia major, by Dual-Energy X-ray Absorptiometry.

(Manufactured by Lunar company of USA) to be measured [@bib1], [@bib2]. The patients׳ demographic characteristics, average five-year hematocrit level (2008--2013), and history of medications were extracted from their records. DEXA was then performed twice to measure BMD in the femur and lumbar region [@bib3], [@bib4]. To reduce measurement errors in each region measured three times mineral density and an average is taken ([Table 2](#t0010){ref-type="table"}).Table 2The average of *Z*-Score before and after intake of drug (confidence interval=95%).Table 2**Demographic features of patientsThe average of *Z*-Score in the first timeThe average of *Z*-Score in the second time*P*-value**Calcium+Vitamin D−2/33±0/78--2/43±0/97*P*\>0.05sex hormones−2/41±0/26−1/91±0/11*P*\<0.02Calcitriol duration−1/44±0/18−1/98±0/36*P*\>0.05bisphosphonate−2/45±0/88−1/88±0/22*P*\<0.02Hydroxy urea use to measure of the first time−2/59±0/96−2/50±0/24*P*\<00.01

To view the impact of drugs on patients before and after drug consumption *Z* and *T* score were measured before and after drug consumption. In measuring the density by Dual-Energy X-ray Absorptiometry each person has three criteria: first index (*Z*): actually indicates Compare between patient׳s bone density and bone density persons are same age and gender. The second index (*T*): the comparison between the patient׳s bone density and bone density persons are same age [@bib5], [@bib6], [@bib7].

*Z*-scores were obtained from BMD measurements and used to decide whether the patients had osteopenia or osteoporosis. Data analysis was performed with software SPSS 20 and the effect of drugs was studied by Wilcoxon test.
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